BOULDER, CO / ACCESSWIRE / July 15, 2024 / Encision Inc. (OTCPK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 fourth quarter that ended March 31, 2024.
The Company posted quarterly net revenue of $1.53 million for a quarterly net loss of $409 thousand, or $(0.03) per diluted share. These results compare to net revenue of $1.81 million for a quarterly net loss of $93 thousand, or $(0.01) per diluted share, in the year-ago quarter. Gross margin on net revenue was 42% in the fiscal 2024 fourth quarter and 56% in the fiscal 2023 fourth quarter. Gross margin decreased in the current year’s fourth quarter compared to last year’s fourth quarter due principally to higher material costs and increased inventory reserves.
The Company posted twelve months net revenue of $6.59 million for a twelve month net loss of $692 thousand, or $(0.06) per diluted share. These results compare to twelve months net revenue of $7.35 million for a twelve months net loss of $324 thousand, or $(0.03) per diluted share. Gross margin on net revenue was 48% in the fiscal 2024 twelve months and 55% in the fiscal 2023 twelve months. Gross margin in the fiscal 2024 twelve months was lower due to higher material costs and increased inventory reserves.
“Fiscal 2024 presented significant challenges for us and for the medical device market in general,” said Gregory Trudel, President and CEO of Encision Inc. “The market has fundamentally changed because of COVID, and as a small medical device company, we constantly have to generate new ways to engage customers and to drive adoption of our technology. We have had success by offering value added programs that often convert into selling opportunities and we are targeting select customer segments to increase focus and close rates. We also are fighting the conversion of standard laparoscopic procedures to those that are using the robot for procedures. We look forward to fiscal 2025 with a strengthening sales channel, a growing sales pipeline, new collaborative relationships, and a new product introduction that will deliver AEM TM Shield Technology to high growth surgical procedures.
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company’s actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company’s distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company’s filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com
Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)
|
Three Months Ended |
Years Ended |
|||||||||||||||
|
|
March 31, 2024 |
March 31, 2023 |
March 31, 2024 |
March 31, 2023 |
||||||||||||
|
Product revenue
|
$ |
1,505 |
$ |
1,801 |
$ |
6,432 |
$ |
6,885 |
||||||||
|
Service revenue
|
20 |
5 |
154 |
464 |
||||||||||||
|
Total revenue
|
1,525 |
1,806 |
6,586 |
7,349 |
||||||||||||
|
Product cost of revenue
|
868 |
786 |
3,371 |
3,314 |
||||||||||||
|
Service cost of revenue
|
11 |
2 |
79 |
2 |
||||||||||||
|
Total cost of revenue
|
879 |
788 |
3,450 |
3,316 |
||||||||||||
|
Gross profit
|
646 |
1,018 |
3,136 |
4,033 |
||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Sales and marketing
|
400 |
539 |
1,634 |
2,033 |
||||||||||||
|
General and administrative
|
426 |
384 |
1,521 |
1,487 |
||||||||||||
|
Research and development
|
222 |
175 |
622 |
816 |
||||||||||||
|
Total operating expenses
|
1,048 |
1,098 |
3,777 |
4,336 |
||||||||||||
|
Operating (loss)
|
(402 |
) |
(80 |
) |
(641 |
) |
(303 |
) |
||||||||
|
Interest expense and other income, net
|
(7 |
) |
(13 |
) |
(51 |
) |
(21 |
) |
||||||||
|
(Loss)
|
(409 |
) |
(93 |
) |
(692 |
) |
(324 |
) |
||||||||
|
Provision for income taxes
|
– |
– |
– |
– |
||||||||||||
|
Net (loss)
|
$ |
(409 |
) |
$ |
(93 |
) |
$ |
(692 |
) |
$ |
(324 |
) |
||||
|
Net (loss) per share-basic and diluted
|
$ |
(0.03 |
) |
$ |
(0.01 |
) |
$ |
(0.06 |
) |
$ |
(0.03 |
) |
||||
|
Weighted average number of basic and diluted shares
|
11,770 |
11,770 |
11,770 |
11,763 |
||||||||||||
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
|
|
March 31, 2024 |
March 31, 2023 |
||||||
|
ASSETS
|
||||||||
|
Cash
|
$ |
43 |
$ |
189 |
||||
|
Accounts receivable
|
891 |
921 |
||||||
|
Inventories
|
1,402 |
1,899 |
||||||
|
Prepaid expenses and other assets
|
90 |
116 |
||||||
|
Total current assets
|
2,426 |
3,125 |
||||||
|
Equipment, net
|
254 |
303 |
||||||
|
Right of use asset
|
901 |
496 |
||||||
|
Patents, net
|
164 |
163 |
||||||
|
Other assets
|
66 |
47 |
||||||
|
Total assets
|
$ |
3,811 |
$ |
4,134 |
||||
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
|
Accounts payable
|
$ |
346 |
$ |
253 |
||||
|
Secured notes
|
42 |
44 |
||||||
|
Line of credit
|
157 |
177 |
||||||
|
Accrued compensation
|
185 |
218 |
||||||
|
Other accrued liabilities
|
120 |
85 |
||||||
|
Accrued lease liability
|
370 |
354 |
||||||
|
Total current liabilities
|
1,220 |
1,131 |
||||||
|
Secured notes
|
67 |
268 |
||||||
|
Accrued lease liability
|
697 |
240 |
||||||
|
Unsecured promissory note
|
– |
– |
||||||
|
Total liabilities
|
1,984 |
1,639 |
||||||
|
Common stock and additional paid-in capital
|
24,372 |
24,348 |
||||||
|
Accumulated (deficit)
|
(22,545 |
) |
(21,853 |
) |
||||
|
Total shareholders’ equity
|
1,827 |
2,495 |
||||||
|
Total liabilities and shareholders’ equity
|
$ |
3,811 |
$ |
4,134 |
||||
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
|
|
Years Ended |
|||||||
|
|
March 31, 2024 |
March 31, 2023 |
||||||
|
Operating activities:
|
||||||||
|
Net (loss) income
|
$ |
(692 |
) |
$ |
(324 |
) |
||
|
Adjustments to reconcile net (loss) income to cash
(used in) operating activities:
|
||||||||
|
Depreciation and amortization
|
85 |
87 |
||||||
|
Share-based compensation expense
|
53 |
52 |
||||||
|
Provision for (recovery from) inventory obsolescence, net
|
12 |
15 |
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Right of use asset, net
|
69 |
(43 |
) |
|||||
|
Accounts receivable
|
30 |
27 |
||||||
|
Inventories
|
485 |
(330 |
) |
|||||
|
Prepaid expenses and other assets
|
8 |
(8 |
) |
|||||
|
Accounts payable
|
93 |
(323 |
) |
|||||
|
Accrued compensation and other accrued liabilities
|
2 |
(14 |
) |
|||||
|
Net cash (used in) provided by operating activities
|
145 |
(861 |
) |
|||||
|
|
||||||||
|
Investing activities:
|
||||||||
|
Acquisition of property and equipment
|
(12 |
) |
(173 |
) |
||||
|
Patent costs
|
(25 |
) |
(10 |
) |
||||
|
Net cash (used in) investing activities
|
(37 |
) |
(183 |
) |
||||
|
|
||||||||
|
Financing activities:
|
||||||||
|
Borrowings from credit facility, net change
|
(21 |
) |
240 |
|||||
|
Borrowings from (paydown of) secured notes
|
(203 |
) |
23 |
|||||
|
Net proceeds (payments) from exercise of stock options
|
(30 |
) |
21 |
|||||
|
Net cash provided by (used in) financing activities
|
(254 |
) |
284 |
|||||
|
|
||||||||
|
Net (decrease) in cash
|
(146 |
) |
(761 |
) |
||||
|
Cash, beginning of period
|
189 |
950 |
||||||
|
Cash, end of period
|
$ |
43 |
$ |
189 |
||||
SOURCE: Encision, Inc.
View the original press release on accesswire.com
View the original press release on accesswire.com
NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…
Diarrhea is one of the most common reasons for veterinary visits for dogs and the…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…